$VVOS

$0.13 -$0.00 (2.28%) Close

$VVOS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 20.1M shares outstanding

Who owns VVOS?

By type of holder

Institutions 2.6% Insiders 22.5% Everyone else 74.9%

Concentration Top 10 holders own 31.1%

Michael C. Skaff 13.8% · V-Co Investors 3 LLC 6.7%

Institutional ownership

2.6%

-6.5 pts vs last qtr

Institutional holders

-3 vs last qtr

Net shares bought

−1.3M

by institutions in Q2 2026

New / sold out

1 / 4

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

IHT Wealth Management, LLC +35.7K
UBS Group AG +28.1K

Biggest sellers in Q2 2026

Armistice Capital, LLC SOLD OUT −1.1M
Vanguard Capital Management LLC −212.7K

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Vivos Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2022–FY2025

+1016.0%

+123.47% a year

Each share's claim on the business

−91.0%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $4.93M

over 4 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years66% Under 1 year34%

Quarterly turnover

39.7%

of institutional shares changed hands

Top 10 managers, median time held

1.3 years

Super Investors

Investment managers reporting VVOS on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
AC Armistice Capital, LLC	—	—	SOLD OUT	—	0.0%
Shares held by quarter Peak holding1.1M (Q1'26) Change over 8 quarters0 Armistice Capital, LLC's full portfolio →
VC Vanguard Capital Management LLC	60.6K	0.30%	−212.7K (−77.8%)	2023	0.0%
Shares held by quarter Peak holding273.3K (Q1'26) Change over 8 quarters+60.6K Share of the company0.300% Vanguard Capital Management LLC's full portfolio →

Armistice Capital, LLC

—

% of company

—

Change vs last qtr

SOLD OUT

Held since

—

Vanguard Capital Management LLC

60.6K

% of company

0.30%

Change vs last qtr

−212.7K (−77.8%)

Held since

2023

23 more super investors behind a free account

See every manager holding Vivos Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting VVOS on Form N-PORT; together they hold 1.7% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$251K	212.7K	1.06%	0.00%	March 31, 2026
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$27.6K	60.6K	0.30%	0.00%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$251K

% of company

1.06%

% of the fund

0.00%

As of

March 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$27.6K

% of company

0.30%

% of the fund

0.00%

As of

June 30, 2026

4 more funds behind a free account

See every fund holding Vivos Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
MC Michael C. Skaff 5%+ holder 13D · 19.9%	2.8M	13.83%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company13.830% Disclosed stake13D · 19.9% View the 13D/G filing →
VI V-Co Investors 3 LLC 5%+ holder 13D · 9.7%	1.4M	6.73%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company6.730% Disclosed stake13D · 9.7% View the 13D/G filing →

Michael C. Skaff

5%+ holder13D · 19.9%

2.8M

% of company

13.83%

Change vs last qtr

—

Held since

—

V-Co Investors 3 LLC

5%+ holder13D · 9.7%

1.4M

% of company

6.73%

Change vs last qtr

—

Held since

—

6 more holders behind a free account

See every insider and 5%+ holder of Vivos Therapeutics Inc.

Comments